Spontaneous Intracerebral Hemorrahge
Conditions
Interventions
Intervention Group:tranexamic acid and intensive blood pressure control within 3 hours after spontaneous intracerebral hemorrhage
Control Group:Blood pressure control according to Chinese guidelines for diagnosis and treatment of acute intracerebral hemorrhage 2019
Sponsors
Huashan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Acute spontaneous intracerebral hemorrhage, diagnosed by clinical history and confirmed by computer tomography, including those involving cerebral ventricular or subarachnoid space; 2. More than 18 years old; 3. Within 3 hours after symptoms occur; 4. Volume of cerebra hemorrhage less than 50 ml.
Exclusion criteria
Exclusion criteria: 1. Intracranial hemorrhage secondary to cerebral tumors, AVM, aneurysm, and cerebral venous thrombosis (It is not necessary to completely exclude secondary cerebral hemorrhage at the time of enrollment, but once the diagnosis of secondary cerebral hemorrhage is clear, the patient will not be included in the study); 2. Recent trauma, cerebral infarction and thrombolytic therapy; 3. Suspected cerebral hemorrhage caused by cerebral amyloid angiopathy; 4. Dementia before illness (previously diagnosed by a medical institution) or severe disability after stroke (mRS >= 3) 5. Coagulation disorders caused by drugs or blood system diseases (coagulation disorders are defined as platelets = 1.8 ) 6. Sinus arrhythmia, marginal rhythm, atrioventricular block of grade II or higher or malignant arrhythmia (arrhythmia and arrhythmia individuals with good pulsation regulated by the pacemaker will not be excluded); 7. Pregnancy or breastfeeding; 8. Life expectancy <3 months; 9. Currently participating in another drug research or clinical trial; 10. The subject or guardian is unwilling to provide his informed consent, or the subject may continue the research and follow-up; 11. The researcher judges that the participants participation in the research will increase their research-related risks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90 days mRS; | — |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS;Hematoma volume;Serious adverse reactions;venous thromboembolic events; | — |
Countries
China
Contacts
Public ContactJIn Hu
Huashan Hospital Affiliated to Fudan University
Outcome results
None listed